Tracer library / [177Lu]Lu-DOTA-JR11
[177Lu]Lu-DOTA-JR11
Also written as [Lu-177]Lu-DOTA-JR11; Lu-177-DOTA-JR11
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 3
What it is
- Compound class
- Radiolabeled somatostatin receptor antagonist peptide (DOTA-conjugated)
- Target / mechanism
- Somatostatin receptor 2 (SSTR2) antagonist PMID 39149492
- Clinical application
- Neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy, including therapy-resistant meningioma and metastatic pheochromocytoma/paraganglioma PMID 32859703
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | >95% | DOTA-JR11 piCHEM, Raaba-Grambach, Austria | 40147849 2025 J Nucl Med Radiolabeling of the DOTA compounds was done at 85°C for 25 min, using ascorbic acid buffer and no-carrier-added [177Lu]LuCl3 |
| Manual synthesis | — | — | >95% | >95% | DOTA-JR11 CPC Scientific, San Jose, CA | 39149492 2024 Res Sq 3.7 MBq (100 μCi) of ammonium acetate buffered [52Mn]MnCl2 (pH 4.5) was added to a 1.5 mL microcentrifuge tube containing 100 μL of 0.25 M ammonium acetate, pH 4.5, and varying concentrations of the ligands (0.1–1.0 nM). The reaction mixtures were incubated at 90°C while shaking for 30 min on a thermomixer (800 RPM). - DOTATATE and DOTA-JR11 were efficiently radiolabeled with > 95% RCY when ~ 5.6 nmol of each ligand was mixed with 3.7 MBq (100 μCi) of [52Mn]MnCl2 |
| Manual synthesis | — | — | 99.0 | 96.6 | DOTA-JR11 | 37389800 2023 EJNMMI Radiopharm Chem The mixture was incubated for 20 min at 90 °C and then left to cool down for 5 min. - [177Lu]Lu-DOTA-JR1199.096.696.596.894.593.7 |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.2024 · J Nucl Med · Prospective · Phase 0
- Radiolabelled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with metastatic pheochromocytoma or paraganglioma: a retrospective pilot study.2026 · Eur J Nucl Med Mol Imaging · Retrospective
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- CPC Scientific, piCHEM
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-JR11, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 7 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 39 from PMID 38423782: 'In this prospective, single-center, open-label phase 0 study (NCT04997317), 6 consecutive patients were included'.